GeoPharma, Inc. Announces Third Quarter Call

LARGO, Fla., Feb. 6 /PRNewswire-FirstCall/ -- GeoPharma, Inc. announced today that it will host a conference call to discuss earning results on Tuesday, February 13, 2007 at 11:30 (ET) with CEO, Mihir Taneja and VP/CFO, Carol Dore-Falcone. Interested parties may participate in the conference call by dialing 1-866-203-2528 and entering passcode 58963376, 5 minutes prior to the initiation of the call. A replay of the conference call will be available from 1:30 PM (ET) on February 13 through February 20, by dialing 1-888-286-8010 and entering passcode 85195477. The Company will release earnings before trading the day of the call.

GeoPharma, Inc. is a rapidly growing pharmaceutical company specializing in the manufacturing and distribution of over-the-counter, nutritional, generic drug and functional food products. The company’s growth strategy is to capitalize on its manufacturing expertise to develop high margin generic or novel drugs for niche markets with high barriers to entry. GeoPharma’s competitive advantage lies in its ability to circumvent or overcome the challenges in these markets. For more about GeoPharma, Inc., go to our websites at www.geopharmainc.com and www.onlineihp.com .

This press release may contain statements, which constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries’ expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company’s management as of the date hereof, and actual results may vary based upon future events, both within and without management’s control. Important factors that could cause such differences are described in the company’s periodic filings with the Securities and Exchange Commission.

GeoPharma, Inc.

CONTACT: Carol Dore-Falcone, VP and CFO of GeoPharma, +1-727-544-8866x244, or cdf@onlineihp.com, Investor relations, Kevin Nally of ZanganiInvestor Community for GeoPharma, +1-908-788-9660 x625, oroffice@zangani.com, or www.zangani.com

MORE ON THIS TOPIC